

Atish D Choudhury

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2081139/publications.pdf>

Version: 2024-02-01

42
papers

3,272
citations

361045

20
h-index

329751

37
g-index

47
all docs

47
docs citations

47
times ranked

6503
citing authors

#	ARTICLE	IF	CITATIONS
1	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	5.8	584
2	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. <i>Nature Biotechnology</i> , 2014, 32, 479-484.	9.4	495
3	Lack of PTEN sequesters CHK1 and initiates genetic instability. <i>Cancer Cell</i> , 2005, 7, 193-204.	7.7	305
4	Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. <i>Cell</i> , 2018, 174, 433-447.e19.	13.5	258
5	Coordination of an Array of Signaling Proteins through Homo- and Heteromeric Interactions Between PDZ Domains and Target Proteins. <i>Journal of Cell Biology</i> , 1998, 142, 545-555.	2.3	219
6	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	0.8	162
7	Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. <i>European Urology</i> , 2019, 76, 89-97.	0.9	158
8	EZH2 inhibition activates a dsRNAâ€“STINGâ€“interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 444-456.	5.7	118
9	Ubiquitination and Proteasomal Degradation of the BRCA1 Tumor Suppressor Is Regulated during Cell Cycle Progression. <i>Journal of Biological Chemistry</i> , 2004, 279, 33909-33918.	1.6	109
10	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	3.2	109
11	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 176-190.	157.7	101
12	Tumor fraction in cell-free DNA as a biomarker in prostate cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	94
13	The Role of Genetic Markers in the Management of Prostate Cancer. <i>European Urology</i> , 2012, 62, 577-587.	0.9	92
14	<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 2094-2100.	0.4	71
15	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 555-563.	2.9	59
16	Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. <i>Integrative Biology (United Kingdom)</i> , 2014, 6, 388-398.	0.6	51
17	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021, 127, 840-849.	2.0	51
18	CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. <i>Cell Reports</i> , 2019, 29, 2355-2370.e6.	2.9	45

#	ARTICLE	IF	CITATIONS
19	Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. <i>Nature Biomedical Engineering</i> , 2022, 6, 257-266.	11.6	32
20	Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. <i>Cancer Research</i> , 2017, 77, 753-765.	0.4	31
21	PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications. <i>Prostate</i> , 2022, 82, .	1.2	20
22	Hyperphosphorylation of the BARD1 Tumor Suppressor in Mitotic Cells*. <i>Journal of Biological Chemistry</i> , 2005, 280, 24669-24679.	1.6	13
23	New Agents in Metastatic Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1403-1409.	2.3	13
24	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K β/δ , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	3.2	11
25	Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?. <i>Journal of Urology</i> , 2021, 205, 1263-1274.	0.2	10
26	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020, 26, 6122-6131.	3.2	9
27	PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	9
28	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 524-532.	2.0	8
29	Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 314-319.	2.0	6
30	Retinoblastoma Loss in Cancer: Casting a Wider Net. <i>Clinical Cancer Research</i> , 2019, 25, 4199-4201.	3.2	5
31	A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 1053-1062.	1.2	4
32	Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2022, 7, 100808.	0.6	4
33	Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer. <i>Current Opinion in Urology</i> , 2020, 30, 30-35.	0.9	3
34	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	2
35	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. <i>Journal of Medical Internet Research</i> , 2019, 21, e12044.	2.1	2
36	Transdermal oestrogen for advanced prostate cancer. <i>Lancet, The</i> , 2021, 397, 556-557.	6.3	1

#	ARTICLE	IF	CITATIONS
37	Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 4055.	1.7	1
38	Abstract 5689: Identify tissue-of-origin in cancer cfDNA by whole genome sequencing. , 2017, , .		1
39	Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. <i>Prostate</i> , 2022, , .	1.2	1
40	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1274-1274.	0.2	0
41	Abstract 3521: Transcriptome analysis of TCGA prostate cancer samples identifies an association of poorer survival and aggressive disease biology with CDC-like kinase (CLK) expression and spliceosome regulation. , 2020, , .		0
42	Towards Biologically Driven Decision-making in Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 924-924.	2.6	0